Cardioprotective effects of trimetazidine: a review
- 1 January 2003
- journal article
- review article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 19 (7), 661-672
- https://doi.org/10.1185/030079903125002261
Abstract
The efficacy of trimetazidine, an anti-ischaemic agent, has been largely assessed and presented in the international literature through its metabolic effects, selective and specific fatty acid oxidation inhibition and lack of haemodynamic effects in stable angina pectoris. As such, trimetazidine has opened up a new class of metabolic agents that reduce fatty acid oxidation: the 3-KAT (3-ketoacyl-CoAthiolase) inhibitors. The aim of this review article is to demonstrate the cardioprotective benefits of trimetazidine, and how this can be translated into positive effects in the treatment of cardiac disorders. Trimetazidine has been assessed in several double-blind randomised studies as a treatment of ischaemic heart disease or as an agent given prior to or during percutaneous transluminal coronary angioplasty, coronary artery bypass grafting and thrombolysis to prevent or limit ischaemia/reperfusion damage in the heart. All these studies demonstrate that trimetazidine protects the heart from the deleterious consequences of ischaemia by switching cardiac metabolism from fatty acid oxidation to glucose oxidation. Study results cast no doubts on the value of the cardioprotective effects of trimetazidine and support the fact that trimetazidine has a direct anti-ischaemic effect on human myocardial cells. Trimetazidine has proven antianginal efficacy, and can be also used in other cardiac diseases with ischaemic signs.Keywords
This publication has 47 references indexed in Scilit:
- Partial fatty acid oxidation inhibitors for stable anginaExpert Opinion on Investigational Drugs, 2002
- Trimetazidine for stable angina pectorisExpert Opinion on Pharmacotherapy, 2001
- A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarctionInternational Journal of Cardiology, 2001
- The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarctionInternational Journal of Cardiology, 1996
- Characteristics of a contemporary population with angina pectorisThe American Journal of Cardiology, 1994
- Regulation of fatty acid oxidation in the mammalian heart in health and diseaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Inhibitory Effect of Trimetazidine on Thrombin-Induced Aggregation and Calcium Entry into Human PlateletsJournal of Cardiovascular Pharmacology, 1994
- Trimetazidine Inhibits Neutrophil Accumulation After Myocardial Ischaemia and Reperfusion in RabbitsJournal of Cardiovascular Pharmacology, 1993
- Improvement of Long-Term Preservation of Isolated Arrested Rat HeartJournal of Cardiovascular Pharmacology, 1993
- Inhibitory effects of trimetazidine dihydrochloride on aggregation, serotonin release and malondialdehyde production in rabbit platelets.The Japanese Journal of Pharmacology, 1988